Helixgate https://validator.w3.org/feed/docs/rss2.html Visualizing Receptor Transport Within Neurons via Transcytosis Hantavirus risk remains low, CDC says, citing its ‘playbook’ response  BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration Webinar: Resolving Target Biology and Compound MOA at Scale: Enabling AI to Chat with Cells on the BioGPU Runtime ASGCT President Terry Flotte Touts Rare Disease Initiatives as His Term Ends Officials say $1.3 billion in Medicaid money to California will be deferred over suspicions of fraud After an apparent cure, a gene editing company struggles to repeat the magic ApexGO: AI-Driven Approach to Faster Antibiotic Discovery Bora inks $122.5M takeover of MacroGenics facility to further US expansion Opinion: Hospitals are silencing doctors online, and it’s fueling the health misinformation crisis Valneva to cut up to 15% of jobs as reduced travel hits vaccine demand STAT+: What the Trump administration wants in its next FDA leader Why AI Alone Isn’t Enough for Oligonucleotide Discovery Cellares and ProTgen Automate Manufacturing of Progenitor T-Cell Therapy for Blood Cancer U.S. overdose deaths fell again in 2025, but some worry about policy and drug supply changes New InFocus eReport: Advances in cancer research FDA’s leadership void leaves biotech with renewed ‘uncertainty’ Abeona pivots to T cells; AstraZeneca’s rare disease drug passes Phase 3 Goodbye Galapagos: chameleon company exits the island, rebrands as Lakefront Lilly data point to ‘maintenance’ strategies for GLP-1 weight loss UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged “It Was Not a Cure”: Musunuru Cautions ASGCT on Baby KJ Promise Post-Hoc: Why FDA Commissioner Marty Makary was ousted Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B ASGCT 2026: Victoria Gray Roadshow Returns to Boston New subpoena suggests DOJ has begun criminal investigation of gender-affirming care Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay Behind Galapagos’ transformation into Lakefront Biotherapeutics Icon opens early-phase research unit in San Antonio, plus satellite clinics to grow trial capabilities Lilly maintains weight loss leadership as Foundayo, Zepbound keep pounds off after switching After ‘most damaging period in FDA history,’ Makary will be hard to replace Tessera reveals strongest data yet for in vivo sickle cell therapy Extreme heat is worsening faster for Black Americans [Podcast] Closing the Distance in Cancer Care Merck KGaA’s clients are stockpiling due to Iran war, supporting guidance boost Gene Therapy ETX101 Improves Seizures and Neurodevelopment in Dravet Syndrome in Phase I/II STAT+: Drug meant to make gene therapy safer may also make it less effective Opinion: Access to air conditioning is critical preventive care. But federal policy treats it as optional STAT+: Bill Cassidy risked his legacy. It may not be enough to save his career Scientist as strategist: expanding the role beyond the bench Mid-sized European drugmakers are snapping up US biotechs. Will the surge continue? Lilly, J&J CEOs top pharma’s highest paid list—again AstraZeneca pens agentic AI licensing deal with Owkin 10x Genomics, Harvard Target Element’s Multiomics Platform in Patent Lawsuit A rare cancer-fighting plant compound has been decoded Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models Home Lilly points to low-dose Zepbound and Foundayo as weight loss maintenance options STAT+: Why Marty Makary was the worst FDA commissioner in 25 years AAVs in Focus: Practical Approaches to Capsid Analytics and Plasmid DNA Control